halofantrine

Trade name: halfan

Small moleculeapprovedOrphan Drug FDA

Approved

Jul 24, 1992

Halofantrine is a blood schizonticidal antimalarial agent with no apparent action on the sporozoite, gametocyte or hepatic stages of the infection. It is used only to treat but not to prevent malaria. Has been marketed by GlaxoSmithKline as HALFAN (halofantrine hydrochloride) in 250 mg tablets indicated for the treatment of adults who can tolerate oral medication and who have mild to moderate malaria (equal to or less than 100,000 parasites/mm3) caused by Plasmodium falciparum or Plasmodium vivax. Among side effects is cardiac arrhythmia. It belongs to the phenanthrene class of compounds that includes quinine and lumefantrine. It was reported that halofantrine binds to hematin in vitro (crystal structure of the complex) and to to plasmpesin, a haemoglobin degrading enzyme unique to the malarial parasites. — NCATS

Clinical trial activity

0 trials · 0 clinical orgs · 1 marketing orgs

Phase 1
0
Phase 2
0
Phase 3
0
Phase 4
0

Timeline

1990s

  1. Nov 4, 1991

    Orphan Drug Designation

  2. Jul 24, 1992

    GlaxoSmithKline — Earliest FDA Approval

  3. Jul 24, 1992

    GlaxoSmithKline — NDA Organization

  4. Jul 24, 1992

    GlaxoSmithKline — NDA Secondary Org

Indications

Mechanism of action

Approval history

  • approvedPriority reviewJul 24, 1992

Chemistry & pharmacology

Loading structure…

SMILES

CCCCN(CCCC)CCC(O)c1cc2c(Cl)cc(Cl)cc2c2cc(C(F)(F)F)ccc12
Mol. weight
500.43 g/mol
Lipinski Ro5
2 violation(s)
Rule of 3
No
Chirality
Racemic Mixture
Inorganic
No
Polymer
No
Delivery
Oral
Availability
Discontinued

Oral

Yes

Parenteral

No

Topical

No

Sources

Also known as

  • 1-(1,3-dichloro-6-trifluoromethyl-9-phenanthryl)-3-di(n-butyl)aminopropanol hcl
  • halfan
  • halfan
  • halfan
  • halfan
  • halfan
  • halofantrina
  • halofantrina
  • halofantrine
  • halofantrine
  • halofantrine
  • halofantrine
  • halofantrine
  • halofantrine
  • halofantrine
  • halofantrine
  • halofantrine
  • halofantrine hcl
  • halofantrine hcl
  • halofantrine hcl
  • halofantrine hydrochloride
  • halofantrine hydrochloride
  • halofantrine hydrochloride
  • halofantrine hydrochloride
  • halofantrine hydrochloride
  • halofantrine hydrochloride
  • halofantrine hydrochloride
  • halofantrinum
  • halofantrinum
  • wr 171669
  • wr-171669
  • wr-171669
  • wr-171,669
  • wr 171,699
  • wr-171699

Organizations

Marketing (2)

OrganizationOrg typeRelationshipDate
GlaxoSmithKlineFor profitNDAJul 24, 1992
GlaxoSmithKlineFor profitNDA2Jul 24, 1992